主要研究者的财务关系与随机对照试验结果:横断面研究
该横断面研究纳入2013年发表于核心临床期刊的190篇论文(195项药物疗效随机对照试验),分析主要研究者与药品生产商存在财务关系与试验阳性结果之间的关联。在调整研究资金来源后,主要研究者存在财务关系与阳性试验结果独立相关(比值比3.57,95%置信区间1.7至7.7)。
要点
- 132项(67.7%)研究的主要研究者与制药业存在财务关系。
- 阳性研究中主要研究者财务关系比例为76%(103/136),阴性研究为49%(29/59)。
- 调整资金来源后,财务关系与阳性结果相关(比值比3.57,95%置信区间1.7至7.7)。
核心结论
- 主要研究者的财务关系与阳性临床试验结果独立相关,这些发现可能提示证据基础存在偏倚。
研究设计与样本
- 横断面研究,随机抽样分析2013年1月1日至2013年12月31日期间Medline收录的核心临床期刊上发表的药物疗效随机对照试验。
- 共190篇论文描述195项研究符合纳入标准,涉及397名主要研究者。
主要发现
- 132项(67.7%)研究的主要研究者与制药业存在财务关系。
- 397名主要研究者中231名(58%)有财务关系,166名(42%)无财务关系。
- 主要研究者报告顾问/咨询费156名(39%)、演讲费81名(20%)、未明确财务关系81名(20%)、酬金52名(13%)、雇佣关系52名(13%)、差旅费52名(13%)、持股41名(10%)、与研究药物相关的专利20名(5%)。
- 主要研究者财务关系在阳性研究中占76%(103/136),在阴性研究中占49%(29/59)。
- 未调整分析中,财务关系与阳性研究结果相关(比值比3.23,95%置信区间1.7至6.1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the association between the presence of individual principal investigators' financial ties to the manufacturer of the study drug and the trial's outcomes after accounting for source of research funding. DESIGN: Cross sectional study of randomized controlled trials (RCTs). SETTING: Studies published in "core clinical" journals, as identified by Medline, between 1 January 2013 and 31 December 2013. PARTICIPANTS: Random sample of RCTs focused on drug efficacy. MAIN OUTCOME MEASURE: Association between financial ties of principal investigators and study outcome. RESULTS: A total of 190 papers describing 195 studies met inclusion criteria. Financial ties between principal investigators and the pharmaceutical industry were present in 132 (67.7%) studies. Of 397 principal investigators, 231 (58%) had financial ties and 166 (42%) did not. Of all principal investigators, 156 (39%) reported advisor/consultancy payments, 81 (20%) reported speakers' fees, 81 (20%) reported unspecified financial ties, 52 (13%) reported honorariums, 52 (13%) reported employee relationships, 52 (13%) reported travel fees, 41 (10%) reported stock ownership, and 20 (5%) reported having a patent related to the study drug. The prevalence of financial ties of principal investigators was 76% (103/136) among positive studies and 49% (29/59) among negative studies. In unadjusted analyses, the presence of a financial tie was associated with a positive study outcome (odds ratio 3.23, 95% confidence interval 1.7 to 6.1). In the primary multivariate analysis, a financial tie was significantly associated with positive RCT outcome after adjustment for the study funding source (odds ratio 3.57 (1.7 to 7.7). The secondary analysis controlled for additional RCT characteristics such as study phase, sample size, country of first authors, specialty, trial registration, study design, type of analysis, comparator, and outcome measure. These characteristics did not appreciably affect the relation between financial ties and study outcomes (odds ratio 3.37, 1.4 to 7.9). CONCLUSIONS: Financial ties of principal investigators were independently associated with positive clinical trial results. These findings may be suggestive of bias in the evidence base.
引用
- Ahn R, Woodbridge A, Abraham A, et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ. 2017. PMID: 28096109. doi:10.1136/bmj.i6770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。